| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/28/1996 | EP0697869A1 Transdermal therapeutic systems for the administration of serotonin agonists |
| 02/28/1996 | EP0469010B1 Cosmetic composition |
| 02/28/1996 | CN1117711A potentiation of temozolomide in human tumour cells |
| 02/28/1996 | CN1117484A Fatty acid derivatives |
| 02/27/1996 | US5494819 Pure culture of Pantoea agglomerans ferm BP-3511 |
| 02/27/1996 | US5494683 Surface modified anticancer nanoparticles |
| 02/27/1996 | US5494677 Tissue-specific implantable therapeutic agent delivery system |
| 02/23/1996 | CA2154807A1 Method of treating or preventing cardiac arrhythmia employing an n-substituted heterocyclic derivative |
| 02/22/1996 | WO1996005289A1 Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor |
| 02/22/1996 | WO1996005225A1 Adrenergic receptor |
| 02/22/1996 | WO1996005221A1 Calcitonin receptor |
| 02/22/1996 | WO1996004930A1 Transferrin compositions to alleviate the side effects of cytotoxic drugs |
| 02/22/1996 | WO1996004928A1 Calcitonin gene related peptide receptor |
| 02/22/1996 | WO1996004924A1 Improved antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use |
| 02/22/1996 | WO1996004912A1 Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes |
| 02/22/1996 | WO1996004908A1 Pharmaceutical formulation containing amoxycillin and potassium clavulanate |
| 02/22/1996 | WO1996004907A1 Pharmaceutical formulation |
| 02/22/1996 | WO1996004901A1 Composition and method for treating anxiety |
| 02/22/1996 | WO1996004900A1 Composition and method for protection against drug dependency |
| 02/22/1996 | WO1996004787A1 Combined virustatic antimediator (covam) treatment of common colds |
| 02/22/1996 | CA2196756A1 Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor |
| 02/22/1996 | CA2196203A1 Combined virustatic antimediator (covam) treatment of common colds |
| 02/22/1996 | CA2195782A1 Composition and method for treating anxiety |
| 02/22/1996 | CA2195779A1 Composition and method for protection against drug dependency |
| 02/21/1996 | EP0479903B1 Substituted imidazoles useful as angiotensin ii blockers |
| 02/21/1996 | CN1116929A Use of compounds having an anti-glucocorticoid activity for the preparation of medicaments intended caments prevention or treatment of symptoms associated with the syndrome of spontaneous or prec..... |
| 02/21/1996 | CN1116926A Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract |
| 02/20/1996 | US5492907 Antipsychotic composition and method of treatment |
| 02/20/1996 | US5492899 Contains carbohydrates, lipids, proteins, vitamins, minerals and rna, mono-,di and triphosphate nucleotides |
| 02/20/1996 | US5492689 Administering simultaneously an antiviral agent and two antiinflammatory compounds; synergistic result in treatment of cold or influenza |
| 02/20/1996 | CA2029015C Pharmaceutical compositions for treating gastrointestinal distress |
| 02/15/1996 | WO1996004388A1 Novel compounds |
| 02/15/1996 | WO1996004386A1 Method of using transdominant negative retroviral integrase in the treatment of retroviral infection |
| 02/15/1996 | WO1996004263A1 Method for the preparation of (±)-calanolide a and intermediates thereof |
| 02/15/1996 | WO1996003990A1 Optic nerve health |
| 02/15/1996 | WO1996003984A1 Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| 02/15/1996 | WO1996003981A1 Growth stimulating factors |
| 02/15/1996 | WO1995019169A3 Treatment of platelet derived growth factor related disorders such as cancer using inhibitors of platelet derived growth factor receptor |
| 02/15/1996 | CA2196200A1 Novel compounds |
| 02/15/1996 | CA2196039A1 Optic nerve health |
| 02/15/1996 | CA2194488A1 Method of using transdominant negative retroviral integrase in the treatment of retroviral infection |
| 02/14/1996 | EP0696456A2 Combination of necrosis inducing substances with substances which are activated by necrosis for the selective treatment of tumours and or inflammatory diseases |
| 02/14/1996 | EP0696455A1 Transferrin compositions to alleviate the side effects of cytotoxic drugs |
| 02/14/1996 | EP0696277A1 Hiv protease inhibitors useful for the treatment of aids |
| 02/14/1996 | EP0696208A1 Oral drug delivery compositions and methods |
| 02/14/1996 | EP0696202A1 Pharmaceutical composition containing thymoctonan and azt |
| 02/14/1996 | EP0696201A1 Supplemented and unsupplemented tissue sealants, methods of their production and use |
| 02/14/1996 | CN1116523A Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract |
| 02/13/1996 | US5491150 Supplementary therpeutic agents for the treatment of immunodeficiency syndrome |
| 02/13/1996 | US5491088 Genetic engineering |
| 02/13/1996 | US5490498 Adding fluorocarbon along with breathing gas which oxygenates the fluorocarbon; treatment of respiratory distress syndrome |
| 02/08/1996 | WO1996003515A2 Surface expression of enzyme in gene directed prodrug therapy |
| 02/08/1996 | WO1996003501A1 Dual hybrid system |
| 02/08/1996 | WO1996003429A1 Stable analogs of bioactive peptides containing disulfide linkages |
| 02/08/1996 | WO1996003151A2 Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy |
| 02/08/1996 | WO1996003150A1 Compositions containing hemicelluloses and polyphenols for treating gastrointestinal disorders |
| 02/08/1996 | WO1996003149A1 Antifungal-wound healing compositions and methods for preparing and using same |
| 02/08/1996 | WO1996003146A1 Retroviral transduction of cells using soluble complement inhibitors |
| 02/08/1996 | WO1996003138A1 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens |
| 02/08/1996 | WO1996003135A1 Pharmaceutical compositions, mainly vaginal suppository, containing many different active ingredients |
| 02/08/1996 | WO1996003130A1 Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri |
| 02/08/1996 | WO1996003129A1 Method of treating sweat-related conditions |
| 02/08/1996 | WO1996003122A2 Use of gabapentin in the treatment of anxiety and panic |
| 02/08/1996 | CA2196052A1 Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy |
| 02/08/1996 | CA2196051A1 Surface expression of enzyme in gene directed prodrug therapy |
| 02/08/1996 | CA2195525A1 Stable analogs of bioactive peptides containing disulfide linkages |
| 02/08/1996 | CA2194973A1 Retroviral transduction of cells using soluble complement inhibitors |
| 02/08/1996 | CA2193852A1 Method of treating sweat-related conditions |
| 02/08/1996 | CA2191603A1 Antifungal-wound healing compositions and methods for preparing and using same |
| 02/07/1996 | EP0695189A1 Treatment of inflammatory bowel disease with ifn-gamma inhibitors |
| 02/07/1996 | EP0695187A1 Compositions for inhibition, control and regression of angiogenesis, containing hyaluronic acid and nsaid |
| 02/07/1996 | EP0695180A1 Novel medical use for gaba agonists |
| 02/07/1996 | CN1116212A Prolonged release preparation and polymers thereof |
| 02/07/1996 | CN1116119A Internal guide therapeutic medicine for rheumatoid disease and making method |
| 02/06/1996 | US5489697 Catalytic condensation of ethylbutyryl acetate and phloroglucinol yields 5,7-dihydroxy-4-propylcoumarin which is acetylated at position 8, then reacted with 4,4-dimethoxy-2-methylbutan-2-ol, then treated with acetal and reduced |
| 02/06/1996 | US5489508 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| 02/05/1996 | CA2155245A1 Use of neutortensin antagonists for the preparation of diuretic drugs |
| 02/01/1996 | WO1996002565A1 Igf/igfbp complex for promoting bone formation and for regulating bone remodeling |
| 02/01/1996 | WO1996002561A1 Interaction trap systems for detecting protein interactions |
| 02/01/1996 | WO1996002261A1 Use of magnesium hydroxide as a stool softener |
| 02/01/1996 | WO1996002251A1 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
| 02/01/1996 | WO1996002245A1 Nitric oxide synthase inhibitors for inhibiting the production of airway mucus |
| 02/01/1996 | WO1996002241A1 Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction |
| 02/01/1996 | WO1996002240A2 Use of inhibitors of human s-cd23 |
| 02/01/1996 | WO1996002236A1 Improved combination dose unit |
| 02/01/1996 | WO1996002231A1 Inhalation composition |
| 02/01/1996 | WO1995035112A3 Modulators of pneumococcal adhesion to cellular targets involving the platelet activating factor receptor, and uses thereof |
| 02/01/1996 | DE4426601A1 Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri Use of a combination product comprising a competitive progesterone antagonist and a progestin for the manufacture of a medicament for treating endometriosis or leiomyomata uteri of |
| 02/01/1996 | CA2195474A1 Igf/igfbp complex for promoting bone formation and for regulating bone remodeling |
| 02/01/1996 | CA2195197A1 Corticotropin-releasing factor-binding-protein inhibitors and their use |
| 02/01/1996 | CA2195122A1 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
| 02/01/1996 | CA2194991A1 Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction |
| 01/31/1996 | EP0694302A1 Compositions containing insaturated fatty acids and an aldose reductase inhibitor for treatment of diabetic complications |
| 01/31/1996 | EP0694301A1 Synergistic combination containing at least a RXR specific ligand and a RAR alpha specific ligand |
| 01/31/1996 | EP0694078A1 Method for screening for receptor agonists |
| 01/31/1996 | EP0693929A1 Method for preventing keratocyte loss |
| 01/30/1996 | US5488064 Benzo 1,3 dioxole derivatives |
| 01/30/1996 | US5488050 Methods and products for treating presbyopia |
| 01/30/1996 | US5487984 Processes for producing tumor necrosis factor |
| 01/30/1996 | CA2031572C Non-alcoholic delivery system for orally ingestible active ingredients |